5 hours ago
1
BalkansCat/iStock Editorial via Getty Images
- Baxdrostat, a candidate for uncontrolled or treatment-resistant hypertension from AstraZeneca (NASDAQ:AZN), met its primary endpoints and all secondary endpoints in a phase 3 study.
- Patients on baxdrostat saw a statistically significant and clinically meaningful reduction in mean seated systolic blood
English (US) ·